Prognostic and predictive effects of primary versus secondary platinum resistance for bevacizumab treatment for platinum-resistant ovarian cancer in the AURELIA trial

Exploratory analyses of time to platinum resistance suggest a better prognosis in bevacizumab-treated patients with secondary vs primary platinum resistance. Progression-free and overall survival benefit from bevacizumab was enhanced in secondary-resistant disease. Our findings should be considered when selecting stratification factors in future trials of anti-angiogenic therapy in this setting.

from Cancer via ola Kala on Inoreader http://ift.tt/25PYrsY
via IFTTT